Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial hemodynamics effect in patients with hearth failure with reduced ejection fraction. However, this have never been investigated in patients with heart failure with preserved ejection fraction (HFpEF). In this study we would like to investigate the effect of 14 days modulation of circulating ketone body levels on cardiac function and exercise capacity in patients with HFpEF and T2D.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Commercially available ketone supplement
Isocaloric placebo
Aarhus University Hospital
Aarhus, Denmark
Cardiac Output (L/min)
Right heart catheterization
Time frame: 14 days ketone ester treatment
Pulmonal wedge capillary Pressure (PCWP)
Right heart catheterization
Time frame: 14 days ketone ester treatment
Exercise capacity (METs)
Cardiopulmonary exercise test
Time frame: 14 days ketone ester treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.